​

AnaptysBio (ANAB) Stock Forecast, Price Target & Predictions

OverviewRevenueOwnershipFinancialsChart

ANAB Stock Forecast

AnaptysBio (ANAB) stock forecast, based on 20 Wall Street analysts, predicts a 12-month average price target of $73.71, with a high of $140.00 and a low of $50.00. This represents a 15.55% increase from the last price of $63.79.

- $30 $60 $90 $120 $150 High: $140 Avg: $73.71 Low: $50 Last Closed Price: $63.79

ANAB Stock Rating

AnaptysBio stock's rating consensus is Buy, based on 20 Wall Street analysts. The breakdown includes 0 Strong Buy (0.00%), 13 Buy (65.00%), 7 Hold (35.00%), 0 Sell (0.00%), and 0 Strong Sell (0.00%).

Buy
Total 20 0 7 13 Strong Sell Sell Hold Buy Strong Buy

ANAB Price Target Upside V Benchmarks

TypeNameUpside
StockAnaptysBio15.55%
SectorHealthcare Stocks 15.45%
IndustryBiotech Stocks 41.48%

Price Target Trends

1M3M12M
# Anlaysts3615
Avg Price Target$67.00$77.67$67.93
Last Closing Price$63.79$63.79$63.79
Upside/Downside5.03%21.76%6.49%
Ratings Trends
DateStrong BuyBuyHoldSellStrong SellTotal
Mar, 26391--13
Feb, 26391--13
Jan, 26381--12
Dec, 25381--12
Nov, 25471--12
Analyst Price Target Forecasts
DateAnalystCompanyPrice TargetPrice when PublishedPrice Target/Price when PublishedPrice Target/Last Closing Price
Mar 06, 2026John LeeTruist Financial$50.00$56.29-11.17%-21.62%
Mar 05, 2026Alex ThompsonStifel Nicolaus$85.00$57.3648.19%33.25%
Mar 04, 2026Emily BodnarH.C. Wainwright$66.00$58.0413.71%3.46%
Jan 07, 2026Michael YeeUBS$70.00$43.9159.42%9.74%
Dec 18, 2025Guggenheim$140.00$46.23202.83%119.47%
Dec 17, 2025Etzer DaroutBarclays$55.00$45.0322.14%-13.78%
Dec 11, 2025Stifel Nicolaus$56.00$44.9524.58%-12.21%
Nov 11, 2025Barclays$70.00$33.98106.00%9.74%
Nov 10, 2025David NierengartenWedbush$50.00$33.2650.33%-21.62%
Nov 10, 2025Joon LeeTruist Financial$36.00$34.285.02%-43.56%
Analyst Rating Forecasts
DateCompanyPrevious RatingNew RatingRating Change
Mar 04, 2026H.C. WainwrightBuyBuyhold
Jan 20, 2026BarclaysOverweightOverweighthold
Dec 18, 2025GuggenheimBuyBuyhold
Dec 17, 2025BarclaysOverweightOverweighthold
Nov 10, 2025WedbushOutperformOutperformhold
Oct 15, 2025WedbushOutperformOutperformhold
Oct 13, 2025BarclaysOverweightinitialise
Sep 30, 2025H.C. WainwrightBuyBuyhold
Aug 12, 2025UBSNeutralNeutralhold
Aug 07, 2025WedbushOutperformOutperformhold

Financial Forecast

EPS Forecast

$-15 $-11 $-7 $-3 $1 $5 Dec 21 Dec 22 Dec 23 Dec 24 Dec 25 Dec 26 Dec 27 Dec 28
Dec 21Dec 22Dec 23Dec 24Dec 25Dec 26Dec 27Dec 28
Reported$-2.11$-4.57$-6.08$-5.12$-0.29---
Avg Forecast$-1.83$-4.53$-6.07$-6.08$-5.36$-5.35$-5.76$-5.69
High Forecast$-0.60$-1.76$-5.95$-5.70$-3.66$-2.69$-1.92$0.16
Low Forecast$-2.67$-8.20$-6.32$-6.22$-7.28$-8.61$-10.23$-13.73
Surprise %15.30%0.88%0.16%-15.79%-94.59%---

Revenue Forecast

$0 $50M $100M $150M $200M $250M Dec 21 Dec 22 Dec 23 Dec 24 Dec 25 Dec 26 Dec 27 Dec 28
Dec 21Dec 22Dec 23Dec 24Dec 25Dec 26Dec 27Dec 28
Reported$63.17M$10.29M$17.16M$91.28M$234.60M---
Avg Forecast$63.17M$9.05M$11.94M$55.92M$35.45M$45.32M$60.90M$79.97M
High Forecast$85.43M$14.70M$14.69M$73.19M$73.97M$46.07M$127.08M$166.87M
Low Forecast$30.52M$4.80M$6.09M$45.09M$7.39M$44.57M$12.70M$16.68M
Surprise %0.01%13.64%43.67%63.24%561.83%---

Net Income Forecast

$-400M $-310M $-220M $-130M $-40M $50M Dec 21 Dec 22 Dec 23 Dec 24 Dec 25 Dec 26 Dec 27 Dec 28
Dec 21Dec 22Dec 23Dec 24Dec 25Dec 26Dec 27Dec 28
Reported$-57.80M$-128.72M$-163.62M$-145.23M$-13.23M---
Avg Forecast$-49.34M$-26.58M$-163.62M$-165.66M$-184.77M$-204.22M$-233.66M$-153.20M
High Forecast$-16.19M$-6.96M$-42.85M$-153.58M$-98.59M$-72.41M$-51.69M$4.42M
Low Forecast$-71.95M$-46.20M$-284.39M$-167.59M$-196.12M$-231.86M$-275.43M$-369.63M
Surprise %17.14%384.26%--12.33%-92.84%---

ANAB Forecast FAQ

Is AnaptysBio stock a buy?

AnaptysBio stock has a consensus rating of Buy, based on 20 Wall Street analysts. The rating breakdown includes 0 Strong Buy, 13 Buy, 7 Hold, 0 Sell, and 0 Strong Sell, reflecting a consensus that AnaptysBio is a favorable investment for most analysts.

What is AnaptysBio's price target?

AnaptysBio's price target, set by 20 Wall Street analysts, averages $73.71 over the next 12 months. The price target range spans from $50 at the low end to $140 at the high end, suggesting a potential 15.55% change from the previous closing price of $63.79.

How does AnaptysBio stock forecast compare to its benchmarks?

AnaptysBio's stock forecast shows a 15.55% upside, outperforming the average forecast for the healthcare stocks sector (15.45%) and underperforming the biotech stocks industry (41.48%).

What is the breakdown of analyst ratings for AnaptysBio over the past three months?

  • March 2026: 23.08% Strong Buy, 69.23% Buy, 7.69% Hold, 0% Sell, 0% Strong Sell.
  • February 2026: 23.08% Strong Buy, 69.23% Buy, 7.69% Hold, 0% Sell, 0% Strong Sell.
  • January 2026: 25.00% Strong Buy, 66.67% Buy, 8.33% Hold, 0% Sell, 0% Strong Sell.

What is AnaptysBio’s EPS forecast?

AnaptysBio's average annual EPS forecast for its fiscal year ending in December 2026 is $-5.35, marking a 1744.83% increase from the reported $-0.29 in 2025. Estimates for the following years are $-5.76 in 2027, and $-5.69 in 2028.

What is AnaptysBio’s revenue forecast?

AnaptysBio's average annual revenue forecast for its fiscal year ending in December 2026 is $45.32M, reflecting a -80.68% decrease from the reported $234.6M in 2025. The forecast for 2027 is $60.9M, and $79.97M for 2028.

What is AnaptysBio’s net income forecast?

AnaptysBio's net income forecast for the fiscal year ending in December 2026 stands at $-204M, representing an 1443.42% increase from the reported $-13.232M in 2025. Projections indicate $-234M in 2027, and $-153M in 2028.